Medifron DBT Co. Ltd (065650) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medifron DBT Co. Ltd (065650) has a cash flow conversion efficiency ratio of -0.472x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-12.73 Billion ≈ $-8.63 Million USD) by net assets (₩27.00 Billion ≈ $18.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Medifron DBT Co. Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Medifron DBT Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Medifron DBT Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Medifron DBT Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medifron DBT Co. Ltd ranked by their cash flow conversion efficiency. Explore earnings quality score of Medifron DBT Co. Ltd to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Salutica Bhd
KLSE:0183
|
-0.102x |
|
Adriatic Metals
LSE:ADT1
|
0.000x |
|
Daesang Corp Preference Shares
KO:001685
|
0.058x |
|
Castle Peak Holdings Public Company Limited
BK:CPH
|
0.145x |
|
ChowChow Cloud International Holdings Limited
NYSE MKT:CHOW
|
0.044x |
|
InnoTherapy Inc
KQ:246960
|
-0.004x |
|
Tira Austenite Tbk
JK:TIRA
|
0.003x |
|
Vakif Menkul Kiymet Yatirim Ortakligi AS
IS:VKFYO
|
-0.031x |
Annual Cash Flow Conversion Efficiency for Medifron DBT Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Medifron DBT Co. Ltd from 2014 to 2024. View Medifron DBT Co. Ltd (065650) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩17.49 Billion ≈ $11.85 Million |
₩-4.54 Billion ≈ $-3.07 Million |
-0.259x | -347.44% |
| 2023-12-31 | ₩36.89 Billion ≈ $25.00 Million |
₩-2.14 Billion ≈ $-1.45 Million |
-0.058x | +38.16% |
| 2022-12-31 | ₩31.09 Billion ≈ $21.07 Million |
₩-2.91 Billion ≈ $-1.97 Million |
-0.094x | -163.79% |
| 2021-12-31 | ₩42.29 Billion ≈ $28.66 Million |
₩-1.50 Billion ≈ $-1.02 Million |
-0.036x | +40.87% |
| 2020-12-31 | ₩27.86 Billion ≈ $18.88 Million |
₩-1.67 Billion ≈ $-1.13 Million |
-0.060x | +75.19% |
| 2019-12-31 | ₩17.69 Billion ≈ $11.99 Million |
₩-4.28 Billion ≈ $-2.90 Million |
-0.242x | -445.39% |
| 2018-12-31 | ₩19.20 Billion ≈ $13.01 Million |
₩-852.48 Million ≈ $-577.71K |
-0.044x | +6.08% |
| 2017-12-31 | ₩24.75 Billion ≈ $16.77 Million |
₩-1.17 Billion ≈ $-793.09K |
-0.047x | -4.98% |
| 2016-12-31 | ₩25.57 Billion ≈ $17.33 Million |
₩-1.15 Billion ≈ $-780.62K |
-0.045x | -529.58% |
| 2015-12-31 | ₩23.80 Billion ≈ $16.13 Million |
₩-170.27 Million ≈ $-115.39K |
-0.007x | -25520.44% |
| 2014-12-31 | ₩24.94 Billion ≈ $16.90 Million |
₩701.96K ≈ $475.71 |
0.000x | -- |
About Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more